Potent inhibition of Lp(a) oxidation by icosapent ethyl (IPE) may have contributed to the cardiovascular risk reduction seen in REDUCE-IT in patients with hypertriglyceridaemia, including those with elevated Lp(a) levels.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.